Imugene Limited
IUGNF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.42M
Close$
$-0.01
119.1% downside
Current Fair Value
119.1% downsideOvervalued by 119.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $14.42 Million |
|---|---|
| Enterprise Value | $18.08 Million |
| Earnings per Share | $-0.32 |
| Beta | 2.09 |
| Outstanding Shares | 349,062,989 |
Return
| Return on Equity | -1936.76% |
|---|---|
| Return on Assets | -757.64% |
| Return on Invested Capital | -1595.50% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 4.11 |
| Enterprise Value to EBIT | -0.13 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | 0.7 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 28, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$968,506
Consensus analyst estimateNext Earnings Call
Expected Date
March 3, 2027
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Imugene Limited
14 employees
CEO: Leslie Chong
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an...